{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:28:17Z","timestamp":1770535697695,"version":"3.49.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijcard.2020.07.027","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T21:06:22Z","timestamp":1595970382000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sympathomodulation in congestive heart failure: From drugs to devices"],"prefix":"10.1016","volume":"321","author":[{"given":"Guido","family":"Grassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino","family":"Seravalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Esler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.07.027_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM196209272671305","article-title":"Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure","volume":"267","author":"Chidsey","year":"1962","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0002-9343(65)90211-1","article-title":"Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure","volume":"39","author":"Chidsey","year":"1965","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.CIR.73.4.615","article-title":"Norepinephrine spillover to plasma in congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity","volume":"73","author":"Hasking","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.73.5.913","article-title":"Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure","volume":"73","author":"Leimbach","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardiores.2005.02.012","article-title":"Sympathetic neuronal regulation of the heart in aging and heart failure","volume":"66","author":"Kaye","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0030","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1161\/01.CIR.92.11.3206","article-title":"Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure","volume":"92","author":"Grassi","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/HJH.0000000000001856","article-title":"Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction","volume":"37","author":"Seravalle","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.HYP.0000255983.32896.b9","article-title":"Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms","volume":"49","author":"Grassi","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0045","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/01.HYP.0000193497.45200.66","article-title":"Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea","volume":"46","author":"Spaak","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0050","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/HJH.0b013e32832e8d0f","article-title":"Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation","volume":"27","author":"Despas","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0055","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/eurheartj\/ehv087","article-title":"The sympathetic\/parasympathetic imbalance in heart failure with reduced ejection fraction","volume":"36","author":"Floras","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM199108293250905","article-title":"Evidence for a selective increase in resting cardiac sympathetic activity in some patients suffering sustained out of hospital ventricular arrhythmias","volume":"325","author":"Meredith","year":"1991","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0065","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0735-1097(95)00332-0","article-title":"Adverse consequences of high sympathetic nervous activity in the failing human heart","volume":"26","author":"Kaye","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0070","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-8703(87)90318-8","article-title":"Predicting survival for an individual with congestive heart failure using he plasma norepinephrine concentration","volume":"114","author":"Rector","year":"1987","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0080","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1053\/euhj.2000.2407","article-title":"Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure","volume":"22","author":"Brunner-La Rocca","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0085","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2008.03.056","article-title":"Increased muscle sympathetic nerve activity predicts mortality in heart failure patients","volume":"135","author":"Barretto","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0090","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.921","article-title":"The autonomic nervous system as a therapeutic target in heart failure: a scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology","volume":"19","author":"Van Bilsen","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0095","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1161\/01.CIR.85.6.2119","article-title":"Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function","volume":"85","author":"Coats","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0100","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0105","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.103.19.2336","article-title":"Acute effects of continuous positive airway pressure on cardiac sympathetic tone in congestive heart failure","volume":"103","author":"Kaye","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/heart.85.2.185","article-title":"Short-term effect of continuous positive airway pressure on muscle sympathetic nerve activity in patients with chronic heart failure","volume":"85","author":"Heindl","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0115","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022479","article-title":"Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea","volume":"348","author":"Kaneko","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1164\/ajrccm.152.2.7633695","article-title":"Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea","volume":"152","author":"Naughton","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.HYP.0000144271.59333.a7","article-title":"Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure","volume":"44","author":"Grassi","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0130","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1093\/eurheartj\/ehy682","article-title":"Splanchnic nerve block for decompensated heart failure: splanchnic-HF","volume":"39","author":"Fudim","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1152\/physrev.1997.77.1.75","article-title":"Neural control of renal function","volume":"77","author":"DiBona","year":"1997","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1152\/physrev.1990.70.4.963","article-title":"Overflow of catecholamine neurotransmitters to the circulation: source, fate and functions","volume":"70","author":"Esler","year":"1990","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0145","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/01.CIR.74.6.1290","article-title":"Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and sub-sensitivity to agonist response","volume":"74","author":"Fowler","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0150","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0155","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0165","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0170","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Eichhorn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(90)91517-E","article-title":"Xamoterol in severe heart failure","volume":"336","author":"The Xamoterol in Severe Heart Failure Study Group","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0180","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cardfail.2004.03.006","article-title":"Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients","volume":"10","author":"De Matos","year":"2004","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0185","first-page":"1796","article-title":"Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure","volume":"46","author":"Cohen-Solal","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.nuclcard.2007.08.006","article-title":"Combined therapy with carvedilol and amiodarone is more effective in improving cardiac symptoms, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with carvedilol therapy alone","volume":"15","author":"Toyama","year":"2008","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0195","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/hc4301.098282","article-title":"Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity","volume":"104","author":"Azevedo","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0200","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ejheart.2004.04.015","article-title":"Selective versus nonselective \u03b2-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization","volume":"7","author":"Al-Hesayena","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0205","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.113.120477","article-title":"Differential effects of nonselective versus selective \u03b2-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure","volume":"54","author":"de Peuter","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2004.12.050","article-title":"The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neural remodeling in patients with heart failure","volume":"106","author":"Chizzola","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0215","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cardfail.2004.03.006","article-title":"Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients","volume":"20","author":"De Matos","year":"2004","journal-title":"J.Card Fail"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0220","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0230","first-page":"H555","article-title":"Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension","volume":"300","author":"Xue","year":"2011","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0235","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/HYPERTENSIONAHA.112.197012","article-title":"Central sympathetic inhibition by mineralocorticoid receptor but not angiotensin II type 1 receptor","volume":"60","author":"Leenen","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0240","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1210\/jc.2010-0823","article-title":"Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism","volume":"95","author":"Kontak","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0245","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2008-2660","article-title":"Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients","volume":"94","author":"Menon","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0250","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/HYPERTENSIONAHA.109.147058","article-title":"Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension","volume":"55","author":"Wray","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0255","first-page":"1279","article-title":"Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure","volume":"43","author":"Kasama","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0260","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2967\/jnumed.107.045427","article-title":"Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure","volume":"48","author":"Kasama","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijcard.2011.12.080","article-title":"Effects of mineral corticoid receptor antagonist spironolactone on cardiac symaptehtic nerve activity and prognosis in patients with chronic heart failure","volume":"167","author":"Kasama","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0270","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/HYPERTENSIONAHA.108.120923","article-title":"Mechanistic insights into diuretic-induced insulin resistance","volume":"52","author":"Dronavalll","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-5273(97)02945-8","article-title":"Sympathetic inhibition with clonidine improves autonimic balance in congestive heart failure","volume":"59","author":"You-hua","year":"1997","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0280","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/01.HYP.38.2.286","article-title":"Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure","volume":"38","author":"Grassi","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0285","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1161\/01.HYP.26.5.719","article-title":"Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy","volume":"26","author":"Manolis","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0290","first-page":"659","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0295","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS). The CONSENSUS Trial study group","volume":"316","author":"Swedberg","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0300","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","author":"Yusuf","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0305","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0310","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0315","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan hart failure survival study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0320","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0167-5273(00)00426-5","volume":"77","author":"Dunselman","year":"2001","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0325","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0330","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0735-1097(94)00417-O","article-title":"Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure","volume":"25","author":"Krum","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0335","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0735-1097(95)00484-X","article-title":"Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure","volume":"27","author":"Dibner-Dunlap","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"issue":"96","key":"10.1016\/j.ijcard.2020.07.027_bb0340","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/01.CIR.96.4.1173","article-title":"Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure","volume":"19","author":"Grassi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0345","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1253\/jcj.65.395","article-title":"Effect of angiotensin-converting enzyme inhibition on sympathetic tone in patients with mild to moderate heart failure","volume":"65","author":"Inoko","year":"2001","journal-title":"Jpn. Circ. J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0350","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/hrt.2005.062463","article-title":"Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure","volume":"92","author":"Kasama","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2004.11.011","article-title":"Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure","volume":"149","author":"Blanchet","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0360","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00005344-200212000-00008","article-title":"Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure","volume":"40","author":"Hikosaka","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0365","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/hrt.2005.062463","article-title":"Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure","volume":"92","author":"Kasama","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0370","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jjcc.2008.09.016","article-title":"Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction","volume":"53","author":"Kawamura","year":"2009","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0375","first-page":"R410","article-title":"Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure","volume":"313","author":"Azevedo","year":"2017","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0380","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":"A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/01.CIR.80.1.65","article-title":"Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings","volume":"80","author":"Ferguson","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0390","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-5273(96)02776-3","article-title":"Acute effects of digitalis and enalapril on the neurohumoral profile in patients with sever congestive heart failure","volume":"57","author":"Khoury","year":"1996","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0395","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/jpet.107.136028","article-title":"Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism","volume":"326","author":"Gao","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0400","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.hfc.2008.01.004","article-title":"Potential autonomic nervous system effects of statins in heart failure","volume":"4","author":"Horwich","year":"2008","journal-title":"Heart Fail. Clin."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0405","first-page":"212.29","article-title":"Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies","author":"Ghosh","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0410","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potenttial pharmacological target","volume":"242","author":"Di Franco","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0415","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effects of the sodium glucose co-transporter 2 ihibitor dapaglifozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0420","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0425","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0430","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2019.1612873","article-title":"Ivabradine for treatment of heart failure","volume":"18","author":"Bocchi","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0435","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0440","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0445","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denenervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0450","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0455","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0460","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0465","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.jacc.2019.04.015","article-title":"Renal denervation update from the international sympathetic nervous system summit: JACC state-of-the-art review","volume":"37","author":"Kiuchi","year":"2019","journal-title":"JACC"},{"key":"10.1016\/j.ijcard.2020.07.027_bb0470","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijcard.2013.10.058","article-title":"Trageting the autonomic nervous system: measuring autonomic function and novel devices for heart failure management","volume":"170","author":"Patel","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0475","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijcard.2012.09.019","article-title":"First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-pilot study","volume":"162","author":"Davies","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0480","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.502","article-title":"Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial","volume":"18","author":"Patel","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0485","first-page":"9779","article-title":"Effect of percutaneous renal sympathetic nerve radiofrequency ablation in patients with severe heart failure","volume":"8","author":"Dai","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0490","first-page":"E153","article-title":"Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: a prospective, randomized, controlled, pilot study","volume":"89","author":"Chen","year":"2017","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0495","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.repc.2016.07.007","article-title":"Effects of percutaneous renal sympathetic denervation on cardiac function and exercise tolerance in patients with chronic heart failure","volume":"36","author":"Gao","year":"2017","journal-title":"Rev. Port. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0500","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10741-017-9629-0","article-title":"Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a systematic review and meta-analysis","volume":"22","author":"Fukuta","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0505","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijcard.2015.08.025","article-title":"Renal sympathetic denervation: a potential alternative strategy for patients with heart failure","volume":"201","author":"Lu","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0510","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17434440.2019.1697230","article-title":"Baroreflex activation therapy systems: current status and future prospects","volume":"16","author":"Seravalle","year":"2019","journal-title":"Exp. Rev. Med. Dev."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0515","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.299","article-title":"Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy","volume":"17","author":"Zile","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0520","first-page":"487","article-title":"Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction","volume":"3","author":"Abraham","year":"2015","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0525","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2018.04.075","article-title":"Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease","volume":"266","author":"Halbach","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0530","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ejhf.138","article-title":"Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function and cardiac haemodynamics in heart failure. A proof-of-concept study","volume":"16","author":"Gronda","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0535","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/HJH.0000000000000603","article-title":"Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction","volume":"33","author":"Gronda","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2020.07.027_bb0540","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1097\/HJH.0000000000001498","article-title":"Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report","volume":"35","author":"Dell'Oro","year":"2017","journal-title":"J. Hypertens."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320334756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320334756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:48:37Z","timestamp":1759092517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320334756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":108,"alternative-id":["S0167527320334756"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.07.027","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sympathomodulation in congestive heart failure: From drugs to devices","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}